Novo Nordisk, the owner of the Ozempic and Wegovy GLP-1 drugs, has announced a deal to work with a Californian biotech firm’s on a weight-loss implant.
The post Novo Nordisk signs pact to assess semaglutide implant appeared first on Just Food.
47 Total View 2 Views Today
